Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | AGER | Q15109 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6160250 | 0.95 | PTPN1 (0.55) | L3MBTL1KDM4ETDP1MAPK8PTPN1 | |
| SCHEMBL11451808 | 0.94 | PTPN1 (0.57) | L3MBTL1KDM4ETDP1MAPK8PTPN1 | |
| SCHEMBL1671161 | 0.92 | KDM4E (0.52) | L3MBTL1KDM4ETDP1MAPK8PTPN1 | |
| SCHEMBL123523 | 0.86 | L3MBTL1 (0.64) | L3MBTL1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL6043383 | 0.85 | KDM4E (0.49) | L3MBTL1KDM4ETDP1PTPN1TSHR | |
| SCHEMBL1505205 | 0.83 | KDM4E (0.50) | L3MBTL1KDM4ETDP1TSHRALDH1A1 | |
| SCHEMBL29173176 | 0.83 | L3MBTL1 (0.60) | L3MBTL1TDP1TSHRALDH1A1MAPT | |
| SCHEMBL6589980 | 0.81 | ALDH1A1 (0.53) | L3MBTL1KDM4ETDP1TSHRALDH1A1 | |
| SCHEMBL19357356 | 0.81 | TDP1 (0.50) | TDP1MAPK8ALDH1A1PLK1 | |
| SCHEMBL1681179 | 0.81 | LMNA (0.61) | L3MBTL1KDM4EPTPN1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040013734-A1 | Mixture of water insoluble drug and polymer | PFIZER INC. | 2004-01-22 | — | — | US | claimed |
| EP-1027886-A2 | Pharmaceutical solid dispersions | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| CN-113873996-B | Personal care compositions and malodor control methods | 株式会社资生堂 | 2025-02-18 | — | — | CN | disclosed |
| US-20100227845-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AND ANALOGS THEREOF AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | WU ZHICAI | 2010-09-09 | — | — | US | disclosed |
| US-20100227845-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AND ANALOGS THEREOF AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | WU ZHICAI | 2010-09-09 | — | — | US | disclosed |
| EP-2211619-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AND ANALOGS THEREOF AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | Merck Sharp & Dohme Corp. (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009051705-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AND ANALOGS THEREOF AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-6794387-B2 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (CGMP PDE5) INHIBITORS; 2-(5-ACETYL-2-BUTOXY-3-PYRIDINYL)-7-ETHYL-5-METHYLIMIDAZO(5,1 -F)(1,2,4)TRIAZIN-4(3H)-ONE FOR EXAMPLE | PFIZER INC. | 2004-09-21 | — | — | US | disclosed |
| US-6756373-B1 | SUCH AS 5-(2-BUTOXY-5-IODO-3-PYRIDINYL)-3-ETHYL-2-(2-METHOXY-ETHYL)-2,6-DIHYDRO-7H -PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; ERECTILE DYSFUNCTION | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| EP-1395589-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE 5 INHIBITORS | Pfizer Limited (GB) | 2004-03-10 | — | — | EP | disclosed |
| EP-1380293-A1 | BONE METABOLISM IMPROVING AGENTS | The Nisshin OilliO, Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-20020177599-A1 | Pharmaceutically active compounds | PFIZER INC. | 2002-11-28 | — | — | US | disclosed |
| WO-2002079203-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE 5 INHIBITORS | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
| US-6440982-B1 | INHIBITORS OF CYCLIC GUANOSINE MONOPHOSPHATE DIESTERASES | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1222190-A1 | 5-(2-SUBSTITUTED-5-HETEROCYCLYLSULPHONYLPYRID-3-YL)-DIHYDROPYRAZOLO[4,3-D]PYRIMIDIN-7-ONES AS PHOSPHODIESTERASE INHIBITORS | Pfizer Limited (GB) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001027112-A1 | 5-(2-SUBSTITUTED-5-HETEROCYCLYLSULPHONYLPYRID-3-YL)-DIHYDROPYRAZOLO[4,3-D]PYRIMIDIN-7-ONES AS PHOSPHODIESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| EP-1092718-A1 | 2-(2-Alkoxy-5-heterocyclylsulphonylphenyl)purin-6-ones as phosphodiesterase inhibitors | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-1092719-A2 | Imidazo[5,1-f][1,2,4]triazine derivatives | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-4181658-A | Certain nicotinamido-n-benzoic acid derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-01-01 | — | — | US | disclosed |
| US-4157395-A | TREATMENT OF DIABETES | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177599-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | L3MBTL1 3733/4885KDM4E 2267/4885TDP1 139/4885 |
| US-20040013734-A1 | Mixture of water insoluble drug and polymer | ABCG2, ABCB1, ABCB11 | L3MBTL1 4425/4885KDM4E 2176/4885TDP1 395/4885 |
| US-20100227845-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AND ANALOGS THEREOF AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | L3MBTL1 4410/4885KDM4E 2757/4885TDP1 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.